Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study

BACKGROUND: Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR). The recommended dosage is an initial load of 400 mg/m(2) intravenously (IV) followed by a weekly maintenance dose of 250 mg/m(2). It has been reported retrospectively that cetuximab efficac...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Invest New Drugs
Asıl Yazarlar: Ho, Cheryl, Sangha, Randeep, Beckett, Laurel, Tanaka, Michael, Lau, Derick H., Eisen, Daniel B., Burich, Rachel A., Luciw, Paul, Khan, Imran, Mack, Philip C., Gandara, David R., Davies, Angela M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2010
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4559347/
https://ncbi.nlm.nih.gov/pubmed/20148348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9396-4
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller